Skip to main content
Clinical Trials/ACTRN12622000115730
ACTRN12622000115730
Not yet recruiting
Phase 4

Test and Treat to End Tuberculosis (TB): Investigating the effect of a screening for, and treatment of, latent TB infection (LTBI) in the general population on the prevalence of TB in that population.

Woolcock Institute of Medical Research0 sites208,000 target enrollmentJanuary 24, 2022

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
atent Tuberculosis Infection
Sponsor
Woolcock Institute of Medical Research
Enrollment
208000
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 24, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Eligibility criteria for TEST phase
  • 1\.Aged 5 years or older on the date of enumeration; AND
  • 2\.Capable of giving informed consent or, if aged \< 15 years, having a parent or guardian who can give consent. Assent will also be routinely sought from children aged 10 to \<15 years; AND
  • 3\.Not currently taking treatment for tuberculosis.
  • Eligibility criteria for TREAT phase
  • 1\.Meet eligibility criteria for testing and consented to screening; AND
  • 2\.Tuberculin skin test (TST) reaction size \>\= 10mm (or \> 0mm if known to be HIV \+ve) AND
  • 3\.Either no abnormality consistent with TB on chest radiograph OR abnormal radiograph but two sputum specimens are culture negative for M. tuberculosis

Exclusion Criteria

  • 1\. Pregnant or planning to be pregnant in next 6 months
  • 2\. Important potential drug interactions with the intervention regimen, defined by attending medical officer in accordance with a schedule.
  • 3\. Known allergy or hypersensitivity to the active substance or any of the ingredients of the study drugs
  • 4\. Has completed a course of treatment for TB within the preceding two years.
  • 5\. Serum transaminases (AST and ALT) are both \>\= 3 x upper limit of normal
  • 6\. Severe or life\-threatening illness that is considered by the attending medical officer to make treatment for LTBI inappropriate.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Transcutaneous pulse oximetry brain monitoring studyPatients with a brain injury requiring invasive brain oxygenInjury, Occupational Diseases, Poisoning
ISRCTN28562529Cyban Pty Ltd15
Completed
Not Applicable
A clinical trial to establish the proper diagnosis and therapy of Hypereosinophilic syndrome.Hypereosinophilic syndrome, chronic eosinophilic leukemia
JPRN-UMIN000008653Kobe University Medical School Hospital30
Active, not recruiting
Not Applicable
First international trial for diagnosia nd treatment of langerhans cell histiocytosis in adults - LCH-A1angerhans cell histiocytosisMedDRA version: 9.1Level: HLTClassification code 10020118Term: Histiocytoses
EUCTR2006-002392-40-ITAZ. DI RILIEVO NAZ. E DI ALTA SPECIALIZZAZIONE OSP. CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI250
Recruiting
Phase 2
Effectiveness of Perilla oil with Mild to Moderate of Dementia PatientDevelopment of the medical and society led to population in the world are long life which rate of height birth in last time relate with be in move to aged elderly. Campaign for control the birth rateDementia&#44alzheimer&#39s disease&#44Perilla frutescens (L.) Britton&#44Omaga3&#44Clinical Trial&#44Randomize Control Trial&#44Cognitive function&#44MOCA
TCTR20150914001Agricultural Research Development Agency (Public Organization)234
Recruiting
Phase 4
The study to identify risk of botulinum toxin treatment failure due to the antibodyHealthy human volunteers, Patient with history of botulinum toxin treatment failure.Enzyme-Linked Immunosorbent Assay, Botulinum Toxins, Immunoglobulins, Antibodies
TCTR20220525004Merz Healthcare (Thailand) Company Limited500